Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments
20/04/2026 13:38
April 20 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA INC - SCHEDULES TYPE C FDA MEETING FOR HARMONIC PROTOCOL AMENDMENTS LANTERN PHARMA INC - LP-300 DEMONSTRATES 8.3-MONTH MEDIAN PROGRESSION-FREE SURVIVAL WITH NO ADDED TOXICITY Source text: ID:nBwW0fsGa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments